Drug Topics e-News:

Having trouble viewing this email? View in a browser.

You are subscribed to %%list.name%% as %%emailaddr%%. Unsubscribe.

Subscribe Now

to Drug Topics e-News

Drug Topics, Voice of the Pharmacist
Part of the Modern Medicine Network

e-News

DrugTopics.com

April 5, 2011

Drug Topics
Home CE DT Blog JP at Large Viewpoints Regulatory and Legal Archives
In This Issue
Metformin ranks highest for diabetes
DT Blog: Drug manufacturers
Jaeger leaves NCPA
OTC proton pump inhibitor label change
Citalopram, irinotecan hydrochloride recalled
Prescription Solutions launches online service
APhA selects Project IMPACT participants
SLE patients found to be nonadherent
5α-reductase inhibitors linked to ED in BPH
Vimovo use in patients with NSAID-related ulcers
Continuing Education
Newest: New drugs of 2010
For pharmacists, from Drug Topics: Continuing education for pharmacists and pharmacy technicians. Go to CE site here
Meetings
Survey
Last month's survey results:
Does your pharmacy use social media (blog, Facebook, Twitter, etc.) as a marketing tool?
Survey Result

Yes 19%

No 76%

We plan on using social media in 2011 5%

This month we would like to know...
Do you carry personal malpractice insurance, in addition to the coverage provided by your employer?
• I am a community pharmacist and I do not carry personal malpractice insurance.

• I am a community pharmacist, and I do carry personal malpractice insurance.

• I am a health-system pharmacist and I do not carry personal malpractice insurance.

• I am a health-system pharmacist and I do carry personal malpractice insurance.
Click Here to Vote

Digital Edition

Drug Topics Digital Edition View Current Edition Subscribe to the Digital Edition

Metformin has highest benefit-risk profile in type 2 diabetes

Evidence supports metformin as a first-line agent to treat type 2 diabetes, according to a study in the online edition of the Annals of Internal Medicine. Read full article.

divider

DT Blog

Bob Spera

A discussion generated by
Drug Topics’ readers, editorial staff, and advisory board

Bob Spera, RPh, community and hospital pharmacist, writer for pharmacy trade journals.

Can drug manufacturers change their philosophy?
Read full article.

divider

Jaeger leaves NCPA; Hoey named CEO

Kathleen Jaeger has resigned as executive vice president and CEO of the NCPA because she disagreed with NCPA executives about the organization's direction. Read full article.

divider

FDA issues labeling change for OTC proton pump inhibitors

The risk of fracture is unlikely in patients taking short-term, low-dose proton pump inhibitors, according to a review of available safety data by FDA. Read full article.

divider

Citalopram, irinotecan hydrochloride recalled

APP Pharmaceuticals Inc. in Schaumburg, Ill., recently recalled 5 lots of irinotecan hydrochloride injection, used to treat recurrent or progressive metastatic colorectal cancer. Read full article.

divider

Prescription Solutions speeds up prior authorizations

Prescription Solutions, a pharmacy benefits manager and a UnitedHealth Group company in Irvine, Calif., recently launched an online service that speeds up approval of prior authorization requests. Read full article.

divider

APhA selects 25 organizations for Project IMPACT: Diabetes

APhA recently announced the first 25 healthcare organizations that will be participating in its Project IMPACT: Diabetes program. Read full article.

divider

Nonadherence to therapy common in SLE

Patients with systemic lupus erythematosus are commonly nonadherent to therapy, according to a recent study published in Arthritis Care & Research. Read full article.

divider

5α-reductase inhibitors in BPH linked with adverse sexual effects

5α-reductase inhibitors may cause persistent erectile dysfunction, depression, and loss of libido, even after discontinuing use, in men being treated for symptoms of benign prostatic hyperplasia and androgenetic alopecia, according to a literature review published in The Journal of Sexual Medicine. Read full article.

divider

Vimovo well tolerated by arthritis patients at risk for gastric ulcers

Naproxen/esomeprazole magnesium (Vimovo, AstraZeneca and Pozen) 500/20-mg delayed-release tablets was generally well tolerated in osteoarthritis patients requiring daily NSAID therapy who were at risk for NSAID-associated ulcers, according to a study published in Current Medical Research & Opinion. Read full article.

divider

Meetings and Events

April 16, 2011 Diabetes, Oral Health, & Nutrition: Interrelationships, Innovations, & Interventions
San Francisco, CA
Health professionals not eligible for continuing medical education credit will receive a certificate of participation
that they may submit to their state licensing board for credit.
Contact:
Joslin Diabetes Center
One Joslin Place
Boston, MA 02215
617-732-2400
www.ProfessionalEd.joslin.org

April 27-30, 2011 AMCP's 23rd Annual Meeting & Showcase
Minneapolis, MN
Contact:
100 North Pitt Street Suite 400
Alexandria, VA 22314
800-827-2627; 703-683-8416

April 30-May 3, 2011 NACDS Annual Meeting
Scottsdale, AZ
Contact:
P.O. Box 34814
Alexandria, Virginia 22334-0814
703-837-4300

May 17-19, 2011 ASCP Spring Conference + Exhibition (formerly known as the ASCP Midyear Conference)
Las Vegas, Nevada
Contact:
Alexandria, VA 22314
Phone: 703-739-1300 or 800-355-2727
Fax: 703-739-1321 or 800-220-1321
[email protected]

May 23-25, 2011 NCPA Legislative Conference
Washington, DC
Contact:
100 Daingerfield Road
Alexandria, VA 22314
800-544-7447

CEC

Connect to Us

Twitter Follow Us on Twitter
Contact Us Contact a Drug Topics editor Click Here
Contact a Drug Topics sales representative Click Here
Learn about direct mail, reprints and classifieds in Drug Topics Click Here

You are subscribed to %%list.name%% as %%emailaddr%%. Click here to unsubscribe or edit your member profile.

To ensure delivery to your inbox, please add us to your address book. If you need help doing this, Click here.

Advanstar Medical Communications Group

Advanstar Communications provides certain customer contact data (such as customers' names, addresses, phone numbers and e-mail addresses) to third parties who wish to promote relevant products, services and other opportunities which may be of interest to you. If you do not want Advanstar Communications to make your contact information available to third parties for marketing purposes, simply call (toll free) 866-529-2922 at any time, or
fax us at 218-740-6417. Outside the U.S., please phone 218-740-6395. Contact us by mail at Advanstar Communications Inc., 131 West First St., Duluth, MN 55802-2065, USA.